Now what's interesting is that the trial that was fully enrolled in Feruary was the COAST trial. That is the Eyelea (Aflibercept) combination which I reckon is going to be by far the tougher to achieve the primary endpoint. If that one should report success (?March/April 2025), things are going to get very interesting. I kind of though the ShORe trial would be the first to enrol. Anyway food for thought.
Now what's interesting is that the trial that was fully enrolled...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
64.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $424.1M | |||
| Open | High | Low | Value | Volume |
| 63.0¢ | 64.0¢ | 62.0¢ | $54.33K | 86.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 36038 | 62.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 8970 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
62.8¢ |
Change
0.000 ( 1.18 %) |
||||
| Open | High | Low | Volume | ||
| 62.5¢ | 63.0¢ | 62.0¢ | 15047 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| OPT (ASX) Chart |